Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    20856802 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery
Condition: Melanoma (Skin)
Intervention: Biological: maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody
2 Active, not recruiting Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma
Condition: Melanoma (Skin)
Intervention: Biological: CP-675,206

Indicates status has not been verified in more than two years